Logo image of ICD

INDEPENDENCE CONTRACT DRILLI (ICD) Stock Fundamental Analysis

NYSE:ICD - New York Stock Exchange, Inc. - US4534156066 - Common Stock - Currency: USD

0.5858  -0.06 (-9.88%)

After market: 0.555 -0.03 (-5.26%)

Fundamental Rating

1

Overall ICD gets a fundamental rating of 1 out of 10. We evaluated ICD against 63 industry peers in the Energy Equipment & Services industry. ICD may be in some trouble as it scores bad on both profitability and health. ICD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ICD had negative earnings in the past year.
In the past year ICD had a positive cash flow from operations.
ICD had negative earnings in each of the past 5 years.
Of the past 5 years ICD 4 years had a positive operating cash flow.
ICD Yearly Net Income VS EBIT VS OCF VS FCFICD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

ICD has a worse Return On Assets (-15.80%) than 92.06% of its industry peers.
With a Return On Equity value of -37.58%, ICD is not doing good in the industry: 87.30% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -15.8%
ROE -37.58%
ROIC N/A
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
ICD Yearly ROA, ROE, ROICICD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10 -20 -30

1.3 Margins

In the last couple of years the Operating Margin of ICD has grown nicely.
Looking at the Gross Margin, with a value of 32.59%, ICD is in the better half of the industry, outperforming 65.08% of the companies in the same industry.
In the last couple of years the Gross Margin of ICD has grown nicely.
The Profit Margin and Operating Margin are not available for ICD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.59%
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
ICD Yearly Profit, Operating, Gross MarginsICD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

ICD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ICD has more shares outstanding
ICD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ICD is higher compared to a year ago.
ICD Yearly Shares OutstandingICD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
ICD Yearly Total Debt VS Total AssetsICD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -1.26, we must say that ICD is in the distress zone and has some risk of bankruptcy.
ICD's Altman-Z score of -1.26 is on the low side compared to the rest of the industry. ICD is outperformed by 88.89% of its industry peers.
The Debt to FCF ratio of ICD is 10.37, which is on the high side as it means it would take ICD, 10.37 years of fcf income to pay off all of its debts.
ICD's Debt to FCF ratio of 10.37 is in line compared to the rest of the industry. ICD outperforms 46.03% of its industry peers.
ICD has a Debt/Equity ratio of 1.08. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of ICD (1.08) is worse than 79.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF 10.37
Altman-Z -1.26
ROIC/WACCN/A
WACC2.02%
ICD Yearly LT Debt VS Equity VS FCFICD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

ICD has a Current Ratio of 1.33. This is a normal value and indicates that ICD is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.33, ICD is not doing good in the industry: 79.37% of the companies in the same industry are doing better.
ICD has a Quick Ratio of 1.28. This is a normal value and indicates that ICD is financially healthy and should not expect problems in meeting its short term obligations.
ICD has a Quick ratio of 1.28. This is in the lower half of the industry: ICD underperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 1.28
ICD Yearly Current Assets VS Current LiabilitesICD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ICD have decreased strongly by -662.07% in the last year.
The Revenue for ICD has decreased by -21.60% in the past year. This is quite bad
Measured over the past years, ICD shows a quite strong growth in Revenue. The Revenue has been growing by 8.06% on average per year.
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%

3.2 Future

The Earnings Per Share is expected to decrease by -46.50% on average over the next years. This is quite bad
The Revenue is expected to decrease by -8.70% on average over the next years.
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ICD Yearly Revenue VS EstimatesICD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ICD Yearly EPS VS EstimatesICD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ICD. In the last year negative earnings were reported.
Also next year ICD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICD Price Earnings VS Forward Price EarningsICD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

ICD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ICD is cheaper than 74.60% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ICD indicates a rather cheap valuation: ICD is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 0.54
EV/EBITDA 4.69
ICD Per share dataICD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as ICD's earnings are expected to decrease with -46.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.5%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ICD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INDEPENDENCE CONTRACT DRILLI

NYSE:ICD (8/28/2024, 8:04:00 PM)

After market: 0.555 -0.03 (-5.26%)

0.5858

-0.06 (-9.88%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)08-07 2024-08-07/bmo
Earnings (Next)10-30 2024-10-30/amc
Inst Owners0.01%
Inst Owner Change0%
Ins Owners75.82%
Ins Owner Change0%
Market Cap8.92M
Analysts80
Price Target3.57 (509.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.38%
Min EPS beat(2)-50.58%
Max EPS beat(2)-2.18%
EPS beat(4)0
Avg EPS beat(4)-48.02%
Min EPS beat(4)-115.7%
Max EPS beat(4)-2.18%
EPS beat(8)4
Avg EPS beat(8)27.37%
EPS beat(12)5
Avg EPS beat(12)-68.42%
EPS beat(16)9
Avg EPS beat(16)-49.21%
Revenue beat(2)2
Avg Revenue beat(2)6.69%
Min Revenue beat(2)2.48%
Max Revenue beat(2)10.9%
Revenue beat(4)3
Avg Revenue beat(4)3.1%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)10.9%
Revenue beat(8)6
Avg Revenue beat(8)2.51%
Revenue beat(12)8
Avg Revenue beat(12)2.8%
Revenue beat(16)9
Avg Revenue beat(16)0.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-48.55%
EPS NQ rev (3m)-25.02%
EPS NY rev (1m)-36.74%
EPS NY rev (3m)-10.78%
Revenue NQ rev (1m)-14.34%
Revenue NQ rev (3m)-18.05%
Revenue NY rev (1m)-3.15%
Revenue NY rev (3m)-5.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF 0.54
P/OCF 0.21
P/B 0.06
P/tB 0.06
EV/EBITDA 4.69
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)1.09
FCFY186.61%
OCF(TTM)2.86
OCFY487.46%
SpS11.83
BVpS10.37
TBVpS10.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.8%
ROE -37.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.59%
FCFM 9.24%
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF 10.37
Debt/EBITDA 4.57
Cap/Depr 58.68%
Cap/Sales 14.9%
Interest Coverage N/A
Cash Conversion 116%
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 1.28
Altman-Z -1.26
F-Score3
WACC2.02%
ROIC/WACCN/A
Cap/Depr(3y)80.67%
Cap/Depr(5y)71.77%
Cap/Sales(3y)20.36%
Cap/Sales(5y)19.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-138.99%
EBIT growth 3YN/A
EBIT growth 5Y79.64%
EBIT Next Year42.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2030.36%
OCF growth 3Y494.79%
OCF growth 5Y30.47%